Mirat Shah

1.1k total citations · 1 hit paper
18 papers, 549 citations indexed

About

Mirat Shah is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mirat Shah has authored 18 papers receiving a total of 549 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mirat Shah's work include Cancer Genomics and Diagnostics (6 papers), HER2/EGFR in Cancer Research (4 papers) and Statistical Methods in Clinical Trials (4 papers). Mirat Shah is often cited by papers focused on Cancer Genomics and Diagnostics (6 papers), HER2/EGFR in Cancer Research (4 papers) and Statistical Methods in Clinical Trials (4 papers). Mirat Shah collaborates with scholars based in United States, Ireland and Israel. Mirat Shah's co-authors include Richard Pazdur, Marc R. Theoret, Atiqur Rahman, Vered Stearns, Laleh Amiri‐Kordestani, Shenghui Tang, Jiang Liu, Jonathon Vallejo, Jeanne Fourie Zirkelbach and Gwynn Ison and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Mirat Shah

17 papers receiving 540 citations

Hit Papers

The Drug-Dosing Conundrum in Oncology — When Less Is More 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Drug-Dosing Conundrum in Oncology — When Less Is More
    2021 180 citations Mirat Shah, Atiqur Rahman et al. New England Journal of Medicine profile →

Peers

Mirat Shah
Jonathon Vallejo United States
DA Berry United States
Jeanne Fourie Zirkelbach United States
Jianchang Lin United States
Joseph C. Del Paggio Canada
NM Hylton United States
Ray Lin United States
Hong Lü United States
Joyce Cheng United States
Jeffrey Skolnik United States
Jonathon Vallejo United States
Mirat Shah
Citations per year, relative to Mirat Shah Mirat Shah (= 1×) peers Jonathon Vallejo

Countries citing papers authored by Mirat Shah

Since Specialization
Citations

This map shows the geographic impact of Mirat Shah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mirat Shah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mirat Shah more than expected).

Fields of papers citing papers by Mirat Shah

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mirat Shah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mirat Shah. The network helps show where Mirat Shah may publish in the future.

Co-authorship network of co-authors of Mirat Shah

This figure shows the co-authorship network connecting the top 25 collaborators of Mirat Shah. A scholar is included among the top collaborators of Mirat Shah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mirat Shah. Mirat Shah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Shah, Mirat, Ting-Yu Chen, Gwynn Ison, et al.. (2025). Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer. Journal of Clinical Oncology. 43(19). 2218–2227. 1 indexed citations
2.
3.
Levit, Laura A., Mirat Shah, Mark J. Ratain, et al.. (2025). Totality of the Evidence: Optimizing Dosage Selection Strategies in Oncology. Journal of Clinical Oncology. 43(25). 2827–2833.
4.
Mehta, Gautam U., Paz J. Vellanki, Yi Ren, et al.. (2024). FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations. The Oncologist. 29(8). 667–671. 10 indexed citations
5.
Shah, Mirat, et al.. (2024). Dosage Optimization: A Regulatory Perspective for Developing Oncology Drugs. Clinical Pharmacology & Therapeutics. 116(3). 577–591. 3 indexed citations
6.
Liu, Jiang, et al.. (2023). Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development. CPT Pharmacometrics & Systems Pharmacology. 13(5). 691–709. 23 indexed citations
7.
Heiss, Brian L., Jonathon Vallejo, Joyce Cheng, et al.. (2023). Dosage optimization in drug development: An FDA Project Optimus analysis of postmarketing requirements issued to repair the cracks.. Journal of Clinical Oncology. 41(16_suppl). 1598–1598. 4 indexed citations
8.
Zirkelbach, Jeanne Fourie, Mirat Shah, Jonathon Vallejo, et al.. (2022). Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients. Journal of Clinical Oncology. 40(30). 3489–3500. 97 indexed citations
9.
Shah, Mirat, Christy Osgood, Anup Amatya, et al.. (2022). FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research. 28(24). 5249–5253. 56 indexed citations
10.
Walsh, Elaine M., John H. Fetting, Deborah K. Armstrong, et al.. (2021). Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. Clinical Breast Cancer. 22(4). 319–325. 8 indexed citations
11.
Mehta, Gautam U., Amy Barone, Diana Bradford, et al.. (2021). US Food and Drug Administration regulatory updates in neuro-oncology. Journal of Neuro-Oncology. 153(3). 375–381. 8 indexed citations
12.
Shah, Mirat, Anna Ferguson, Ravi Varadhan, et al.. (2021). Developing Workshops to Enhance Hope Among Patients With Metastatic Breast Cancer and Oncologists: A Pilot Study. JCO Oncology Practice. 17(6). e785–e793. 12 indexed citations
13.
Shah, Mirat, Atiqur Rahman, Marc R. Theoret, & Richard Pazdur. (2021). The Drug-Dosing Conundrum in Oncology — When Less Is More. New England Journal of Medicine. 385(16). 1445–1447. 180 indexed citations breakdown →
14.
Murphy, Adrian, Marianna Zahurak, Mirat Shah, et al.. (2020). A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer. Clinical and Translational Science. 13(6). 1178–1188. 35 indexed citations
15.
Sedhom, Ramy, Arjun Gupta, Mirat Shah, et al.. (2020). Oncology Fellow–Led Quality Improvement Project to Improve Rates of Palliative Care Utilization in Patients With Advanced Cancer. JCO Oncology Practice. 16(8). e814–e822. 3 indexed citations
16.
McLaughlin, Vallerie V., Anna R. Hemnes, Kristin B. Highland, et al.. (2019). P3671Selexipag dosing and titration in the first 500 patients enrolled in SPHERE (SelexiPag: tHe UsErs dRug rEgistry). European Heart Journal. 40(Supplement_1). 1 indexed citations
17.
Shah, Mirat, et al.. (2018). CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?. PubMed. 32(5). 216–22. 102 indexed citations
18.
Droz, J P, Éric Baudin, В. С. Медведев, et al.. (2006). Activity of irofulven (IROF) combined with capecitabine (CAPE) in patients (pts) with advanced thyroid carcinoma: Phase II international multicenter study (preliminary results). Journal of Clinical Oncology. 24(18_suppl). 15511–15511. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathon Vallejo Breakdown of academic impact, for papers by DA Berry Breakdown of academic impact, for papers by Jeanne Fourie Zirkelbach Breakdown of academic impact, for papers by Jianchang Lin Breakdown of academic impact, for papers by Joseph C. Del Paggio Breakdown of academic impact, for papers by NM Hylton Breakdown of academic impact, for papers by Ray Lin Breakdown of academic impact, for papers by Hong Lü Breakdown of academic impact, for papers by Joyce Cheng Breakdown of academic impact, for papers by Jeffrey Skolnik
Rankless by CCL
2026